MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has closed its previously announced public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $28.00 per share. All of the shares were sold by Dermira. Dermira estimates net proceeds to Dermira from the offering to be approximately $135.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses.
Leerink Partners LLC, Cowen and Company, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering. Needham & Company, LLC acted as co-manager.
This offering was made pursuant to a shelf registration statement on Form S-3 that was filed by Dermira with the Securities and Exchange Commission (“SEC”) on November 2, 2015, as amended by Amendment No. 1 filed with the SEC on November 13, 2015, and declared effective by the SEC on November 24, 2015. This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at [email protected], or by telephone at 800-808-7525, ext. 6142; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 631-274-2806; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 212-518-9658, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy Dermira’s common stock, nor shall there be any sale of Dermira’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]